
STAT+: Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid…

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid…
.jpg)
Next year, two curative gene therapies could be approved for sickle cell disease. Yet drugmakers…
.jpg)
Sickle cell disease features prominently at this year’s virtual meeting of the European Hematology Association,…